Charles River’s capabilities -include vaccine and vector safety studies in multiple species. These studies provide not only efficacy and safety testing data for your vaccines and other anti-infective agents, but also support your pharmacologic/toxicologic evaluation of gene therapy constructs. We design and perform studies in CDC-approved quarantine facilities with BSL-2 ratings to fulfill your preclinical regulatory needs in a GLP-compliant environment.
- Viral, parasitic, and bacterial vaccines
- Both subunit and live vaccines
- Various small molecule anti-infectious agents and immune enhancers
- DNA and viral vectors
- Multiple routes of vector/vaccine administration
Neurovirulence Safety Testing
Our scientists also offer neurovirulence safety testing, since many immunogenic attenuated vaccines are known to possess residual neurovirulence following introduction to the brain. Using direct intracerebral or intrathalamic injection, we conduct these studies to assess the safety of new vaccines and to evaluate the continued safety of established vaccine seed stocks following directed modification or changes in the manufacturing process.
Testing Design Features
- Intracerebral or intrathalamic dosing
- Clinical pathology analyses
- Viral titer and antiviral antibody analyses
- Anatomical pathology evaluation
- Vector biodistribution by quantitative PCR
Additional information about our Vaccine and Vector Safety Testing capabilities is available in The SourceSM, our new online scientific and educational information center. To register for The SourceSM, please click here. If you are already a member, click here to login.
If you have any questions, please contact us at 1.877.CRIVER.1 or firstname.lastname@example.org.